IP Verse

Treatment Of Metabolic Disorders In Canine Animals - EP3485890

The patent EP3485890 was granted to Boehringer Ingelheim Vetmedica on May 10, 2023. The application was originally filed on Jan 20, 2015 under application number EP18208143A. The patent is currently recorded with a legal status of "Revoked".

EP3485890

BOEHRINGER INGELHEIM VETMEDICA
Application Number
EP18208143A
Filing Date
Jan 20, 2015
Status
Revoked
Sep 5, 2025
Publication Date
May 10, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

CEVA SANTE ANIMALEFeb 9, 2024CABINET BECKER ASSOCIESADMISSIBLE
CEVA SANTE ANIMALEFeb 9, 2024CABINET BECKER ET ASSOCIESADMISSIBLE

Patent Citations (53) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP1213296
DESCRIPTIONEP1344780
DESCRIPTIONEP1354888
DESCRIPTIONEP1489089
DESCRIPTIONWO0127128
DESCRIPTIONWO03099836
DESCRIPTIONWO2004007517
DESCRIPTIONWO2004080990
DESCRIPTIONWO2005012326
DESCRIPTIONWO2005092877
DESCRIPTIONWO2006034489
DESCRIPTIONWO2006064033
DESCRIPTIONWO2006117359
DESCRIPTIONWO2006117360
DESCRIPTIONWO2006120208
DESCRIPTIONWO2007025943
DESCRIPTIONWO2007028814
DESCRIPTIONWO2007031548
DESCRIPTIONWO2007093610
DESCRIPTIONWO2007114475
DESCRIPTIONWO2007128749
DESCRIPTIONWO2007140191
DESCRIPTIONWO2008002824
DESCRIPTIONWO2008013280
DESCRIPTIONWO2008042688
DESCRIPTIONWO2008049923
DESCRIPTIONWO2008055870
DESCRIPTIONWO2008055940
DESCRIPTIONWO2008069327
DESCRIPTIONWO2008116179
DESCRIPTIONWO2009014970
DESCRIPTIONWO2009022008
DESCRIPTIONWO2009022020
DESCRIPTIONWO2009035969
DESCRIPTIONWO2010023594
DESCRIPTIONWO2011039107
DESCRIPTIONWO2011039108
DESCRIPTIONWO2011117295
DESCRIPTIONWO2014016381
OPPOSITIONEP2368552
OPPOSITIONUS2008234367
OPPOSITIONUS2011212905
OPPOSITIONUS8283454
OPPOSITIONUS8361972
OPPOSITIONWO0127128
OPPOSITIONWO0174834
OPPOSITIONWO03099836
OPPOSITIONWO2006034489
OPPOSITIONWO2007128749
OPPOSITIONWO2010092123
OPPOSITIONWO2014016381
SEARCHEP2368552
SEARCHWO2010092123

Non-Patent Literature (NPL) Citations (26) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BEAM et al., Vet. Ophtalmol., (19990000), vol. 2, pages 169 - 172
DESCRIPTION- CATCHPOLE et al., Diabetologia, (20050000), vol. 48, pages 1948 - 1956
DESCRIPTION- NELSON et al., J small Anim Pract, (20000000), vol. 41, pages 486 - 490
DESCRIPTION- VERKEST, Vet J
DESCRIPTION- WANG et al., J Diabet. Compl.
EXAMINATION- PASZKIEWICZ REBECCA L. ET AL, "Dapagliflozin Improves Insulin Sensitivity in the Obese Prediabetic Canine", DIABETES, (20180701), vol. 67(Supplement_1), doi:https://doi.org/10.2337/db18-113-LB, pages 113 - LB, XP055980990
OPPOSITION- D36: EXPERIMENTAL REPORT
OPPOSITION- Ema, "Canagliflozin", Assessment report EMA/374133/2013, (20130919), pages 1 - 115, XP093166088
OPPOSITION- Ema, "Forxiga", Assessment report EMEA/H/C/002322, (20120918), pages 1 - 170, XP093165359
OPPOSITION- Ema, "Jardiance", Assessment Report EMA/CHMP/137741/2014, (20140320), pages 1 - 99, XP093166086
OPPOSITION- FDA, "Guidance for Industry - Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers", Food and Drug Administration, (20050701), pages FP-3, 1 - 27, URL: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM078932.pdf, XP055294866
OPPOSITION- Nelson R. W., "Oral medications for treating diabetes mellitus in dogs and cats", JOURNAL OF SMALL ANIMAL PRACTICE, (20001101), vol. 41, pages 486 - 490, XP093194860
OPPOSITION- Paszkiewicz Rebecca L., Richard N. Bergman; Isaac Asare Bediako; Hasmik J. Mkrtchyan; V. Sashi Gopaul; Hsiu-Chiung Yang; Eva Lundborg; Stella Kim; Ivan Formentini; Cathryn M. Kolka, "113-LB: Dapagliflozin Improves Insulin Sensitivity in the Obese Prediabetic Canine", Clinical Diabetes/Therapeutics - POSTERS, (20180101), page LB32, XP093194858
OPPOSITION- Mahmood, I., "Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development", Advanced Drug Delivery Reviews, Elsevier, Amsterdam , NL, Amsterdam , NL , (20070930), vol. 59, no. 11, doi:10.1016/j.addr.2007.05.015, ISSN 0169-409X, pages 1177 - 1192, XP022312896
OPPOSITION- Wenbin Zhang; Ajith Welihinda; Jordan Mechanic; Haifeng Ding; Liangcheng Zhu; Yuan Lu; Zhongping Deng; Zelin Sheng; Binhua Lv; Yuanwei Chen; Jacques Y. Roberge; Brian Seed; Yong-Xiang Wang;, "EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbAlevels in db/db mice and prolongs the survival of stroke-prone rats", Pharmacological Research, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20110102), vol. 63, no. 4, doi:10.1016/j.phrs.2011.01.001, ISSN 1043-6618, pages 284 - 293, XP028141921
OPPOSITION- I. U. Emmerich, "Neue Arzneimittel für Kleintiere 2012", TIERAERZTLICHE PRAXIS = VETERINARY MEDICAL JOURNAL. AUSGABE K, KLEINTIERE/HEIMTIERE, SCHATTAUER, STUTTGART,, DE, DE , (20130401), doi:10.1055/s-0038-1623716, ISSN 1434-1239, pages 237 - 243, XP093166099
OPPOSITION- R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, D E Sharp, R A Bakker, M Mark, T Klein, & P Eickelmann, "Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Introduction", Diabetes Obesity and Metabolism, (20120101), vol. 14, doi:10.1111/j.1463-1326.2011.01517.x, pages 83 - 90, XP055228524
OPPOSITION- K Yamamoto; S Uchida; K Kitano; N Fukuhara; L Okumura‐Kitajima; E Gunji; A Kozakai; H Tomoike; N Kojima; J Asami; H Toyoda; M Arai; T Takahashi; K Takahashi, "TS‐071 is a novel, potent and selective renal sodium‐glucose cotransporter 2 (SGLT2) inhibitor with anti‐hyperglycaemic activity", British journal of pharmacology, Wiley-Blackwell, UK, UK , (20110805), vol. 164, no. 1, doi:10.1111/j.1476-5381.2011.01340.x, ISSN 0007-1188, pages 181 - 191, XP071171135
OPPOSITION- Rao N. V. S. Mamidi, "Metabolism and Excretion of Canagliflozin in Mice, Rats, Dogs, and Humans", Drug Metabolism and Disposition, Pharmacology and Experimental Therapeutics, US, US , (20140501), vol. 42, no. 5, doi:10.1124/dmd.113.056440, ISSN 0090-9556, pages 903 - 916, XP093166095
OPPOSITION- Tirmenstein M; Dorr T E; Janovitz E B; Hagan D; Abell L M; Onorato J M; Whaley J M; Graziano M J; Reilly T P, "Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor", INTERNATIONAL JOURNAL OF TOXICOLOGY, Sage Publications, Inc., US, US , (20130901), vol. 32, no. 5, doi:10.1177/1091581813505331, ISSN 1091-5818, pages 336 - 350, XP008175509
OPPOSITION- Abdul-Ghani Muhammad A., Et Al, "Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes", ENDOCRINE REVIEWS, The Endocrine Society, US, US , (20110801), vol. 32, no. 4, doi:10.1210/er.2010-0029, ISSN 0163-769X, pages 515 - 531, XP055879244
OPPOSITION- Kiichiro Ueta, "Reduction of Renal Transport Maximum for Glucose by Inhibition of Na+-Glucose Cotransporter Suppresses Blood Glucose Elevation in Dogs", Biological & pharmaceutical bulletin, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO., JP, JP , (20051018), vol. 29, no. 1, doi:10.1248/bpb.29.114, ISSN 0918-6158, pages 114 - 118, XP093166093
OPPOSITION- Kirk L. Hamilton, "Robert K. Crane—Na+-glucose cotransporter to cure?", Frontiers in Physiology, Frontiers Research Foundation, CH, CH , (20130301), vol. 4, doi:10.3389/fphys.2013.00053, ISSN 1664-042X, pages 1 - 5, XP093166091
OPPOSITION- Özant Helvacı, "A Story of Serendipities: From Phlorizin to Gliflozins", EXPERIMENTAL AND CLINICAL TRANSPLANTATION, MIDDLE EAST SOCIETY FOR ORGAN TRANSPLANTATION, RIYADH, SA, SA , (20230601), vol. 21, no. Suppl 2, doi:10.6002/ect.IAHNCongress.25, ISSN 1304-0855, pages 105 - 108, XP093166082
SEARCH- GE XU ET AL, "Design, Synthesis, and Biological Evaluation of Deuterated C -Aryl Glycoside as a Potent and Long-Acting Renal Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes", JOURNAL OF MEDICINAL CHEMISTRY, (20140227), vol. 57, no. 4, doi:10.1021/jm401780b, ISSN 0022-2623, pages 1236 - 1251, XP055119035 [PX] 1-14 * abstract *
SEARCH- TIRMENSTEIN M ET AL, "Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor", INTERNATIONAL JOURNAL OF TOXICOLOGY, TAYLOR AND FRANCIS, WASHINGTON, DC, US, (20130901), vol. 32, no. 5, doi:10.1177/1091581813505331, ISSN 1091-5818, pages 336 - 350, XP008175509 [X] 1-7,9-11,13-14 * abstract * * table I * [I] 8

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents